TickerFacts.

Indivior Pharmaceuticals, Inc. (INDV): Capital Expenditures

Annual figures by period end, from SEC filings.

$66.00M
Year ended 2025-12-31
$71.00M
Trailing 12 months to 2026-06-30
+136.3%
3-year compound annual growth
2022-12-31: $5.00M2023-12-31: $8.00M2024-12-31: $29.00M2025-12-31: $66.00M$66.00M
2022-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$66.00M+127.6%2026-02-26, From 2025-01-01
2024-12-31$29.00M+262.5%2026-02-26, From 2024-01-01
2023-12-31$8.00M+60.0%2026-02-26, From 2023-01-01
2022-12-31$5.00Mn/a2025-03-03, From 2022-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Indivior Pharmaceuticals, Inc. (INDV)2025-12-31$66.00M+127.6%
Prestige Consumer Healthcare Inc. (PBH)2026-03-31$11.18M+35.9%
Acadia Pharmaceuticals Inc (ACAD)2025-12-31$4.69M+796.7%
Alkermes plc. (ALKS)2025-12-31$40.42M+20.7%
Phibro Animal Health Corp (PAHC)2026-06-30$59.09M+54.3%
Madrigal Pharmaceuticals, Inc. (MDGL)2025-12-31$467.0K-68.1%
Ionis Pharmaceuticals Inc (IONS)2025-12-31$51.44M+13.6%
PTC Therapeutics, Inc. (PTCT)2025-12-31$8.86M+36.3%
ANI Pharmaceuticals Inc (ANIP)2025-12-31$13.84M-14.8%

Compare INDV, PBH, ACAD, ALKS side by side · Screen every company in Pharmaceutical Preparations ↗